|Product Categories||Proteins||Antibodies||ELISA Kits||cDNA Clones|
|Number of Products|
* Being developed Tell us your requirement so that the products of interest be placed on the priority list.
The term "tumor antigen" has been given a new and much more precise definition as a result of important developments in immunology over the last decade, particularly in the area of antigen presentation and antigen recognition. Tumor antigen must be recognized by specific immune effector cells and/or antibodies and be produced by tumor cells. Among the tumor antigens, some may be tumor specific while others may also be expressed by normal tissues. Cancer cells have accumulated mutations that are possibly recognized as non-self by the immune system. These mutations are different for each tumor. Sometimes, these mutations trigger an immune response. These antigens are referred to as Specific Tumor Antigens (STA). STAs can be derived from intracellular or extracellular proteins, and can be presented in a way that they can be recognized by T-cells. Cancer cells also produce antigens that are sometimes common in a certain subpopulation of tumors. These antigens are considered as Common Tumor Antigens (CTA). CTAs can be used as a marker to categorize the tumor, or to monitor disease progression. Usually, a CTA is exposed to the extracellular environment and can be recognized by antibodies.